Results 31 to 40 of about 12,265 (153)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Cost Effectiveness and Resource Allocation, 2008
Background Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain.
Matthews Jane P, Hurley Susan F, Guymer Robyn H   +2 more
doaj   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola, Pekko Hujanen, Hannu Uusitalo, Hannele Uusitalo‐Järvinen   +3 more
wiley   +1 more source

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab

Indian Journal of Ophthalmology, 2015
Background: To investigate visual and anatomical outcomes in eyes with exudative age-related macular degeneration treated with intravitreal aflibercept following prior treatment with intravitreal ranibizumab.
Daniel Sanju Narayan, James Muecke
doaj   +1 more source

Visual acuity is reduced with increasing central retinal thickness, but also with higher age and female sex in diabetic macular oedema

Acta Ophthalmologica, EarlyView.
Abstract Introduction The increasing number of patients with diabetes has increased the incidence of diabetic macular oedema (DME) with the accompanying risk of developing visual loss. The purpose of the present study was to describe the contributions of increased central retinal thickness (CRT) and other risk factors to the reduction in visual acuity ...
Signe Krejberg Jeppesen, Toke Bek
wiley   +1 more source

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema

Case Reports in Ophthalmology, 2015
Background/Aims: Bevacizumab and ranibizumab are routinely used to treat diabetic macular edema (DME). We aim to evaluate the usefulness of switching to ranibizumab therapy following bevacizumab treatment failure in eyes with DME. Methods: We performed a
Joel Hanhart, Itay Chowers
doaj   +1 more source

Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion

BMC Ophthalmology
Objective To compare the effectiveness and safety of three loading doses of bevacizumab and ranibizumab for macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods This retrospective study included 49 patients with BRVO. The patients were
Sibel Coşkun Akdemir, Nurdan Gamze Taşlı   +1 more
doaj   +1 more source

Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema

BMC Ophthalmology, 2022
Background The goal of this work is to assess progression of diabetic macular edema (DME) following intravitreal ranibizumab injection compared to subtenon triamcinolone acetonide injection at cataract operation. Methods Retrospective analysis of 73 eyes
Mahmoud Mohammed Ahmed Ali Khalil, Hosam Othman Mansour, Ahmed Mohamed Raafat Tawfik, Ahmed Gomaa Elmahdy   +3 more
doaj   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials

BMC Ophthalmology, 2018
Background To evaluate the relative efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of neovascular age-related macular degeneration (AMD). Methods Systematic literature review identifying RCTs comparing
Chu Luan Nguyen, Lawrence J. Oh, Eugene Wong, Joe Wei, Michael Chilov   +4 more
doaj   +1 more source